No abstract available.
Sarcoma*

No abstract available.
Endoderm* ; Endodermal Sinus Tumor*

No abstract available.
Rhabdomyosarcoma*

Wilms' tumor is one of the most common primary malignant tumors of the kidney during infancy and childhood and is known to be originated from the primitive cells of metanephric blastema. It presents difficulties when encountered in deciding the presence of anaplasia or in differentiating it from other renal tumors of childhood with different biologic behavior because of its diverse histologic patterns and varying degrees of differentiation. Evaluation of clinical and histopathologic features in terms of prognostication was done of 32 cases of Wilms' tumor which were surgically resected and diagnosed in the period from January 1979 through June 1992. Immunohistochemical reaction for cytokeratin, vimentin, actin and desmin was also analysed on all cases of Wilms' tumor in conjunction with clear cell sarcoma of the kidney(CCSK), malignant rhabdoid tumor of the kidney(MRTK) and congenital mesoblastic nephroma(CMN) to assess the validity of immunohistochemistry in differentiating Wilms' tumor from these renal tumors. Twenty four(75%) cases were diagnosed before the age of 5 and 40.7% were under 2 years old. Mixed type was most common(62.5%), followed by epithelial, blastemal and stromal predominant type in descending order of frequency. Anaplasia was observed in 3 cases(9.4%), two of which were epithelial predominant type and one blastemal predominant type. Treatment modality and presence of anaplasia were significantly correlated with 5 year survival rate of patients. Immunohistochemical stain revealed that all epithelial component of Wilms' tumor were positive for cytokeratin and 56.3% of Wilms' tumor had blastemal component which were positive for both cytokeratin and vimentin. Twenty cases(62.5%) of Wilms' tumor had blastemal component which were positive for cytokeratin with a proportion of more than 5% of reactive cells. Stromal component of Wilms' tumor generally did not show differentiation into the specialized type of tissue and all revealed positive reactions for vimentin among which some revealed positive reactions for actin. Only 3 out of 6 cases with rhabdomyoblastic differentiation were positive for desmin. CCSK, MRTK and CMN which have different biologic behavior and treatment modality compared to Wilm's tumor showed positivity only for vimentin and/or actin. In summary, treatment modality and presence of anaplasia are significantly correlated with patients' survival and the immunohistochemical stain for cytokeratin is very helpful in confirming the presence of blastemal component and useful in the differential diagnosis of Wilms' tumor from other kinds of pediatric renal tumors.
Child ; Male ; Female ; Humans ; Diagnosis, Differential

Coagulation involves the regulated sequence of proteolytic activation of a series of proteins to achieve appropriate and timely hemostasis in an injured vessel. In the non-pathological state, the inciting event involves exposure of circulating factor VIIa to extravascularly expressed tissue factor, which brings into motion the series of steps which results in cell based model of coagulation. In the new concepts of coagulation system, initiation, amplification and propagation steps are involved to converse of fibrinogen to fibrin. The precisely synchronized cascade of events is counter-balanced by a system of anticoagulant mechanisms. Developmental hemostasis refers to the age-related changes in the coagulation system that are most marked during neonate and childhood. An understanding of these changes in crucial to the accurate diagnosis of hemostatic abnormalities in neonate and children. This review aims to elucidate the main events within the coagulation cascade as it is currently understood to operate in vivo, and also a short review of the anticoagulants as they relate to this model. Also this paper describes the common pitfalls observed in the clinical data related to the coagulation system in neonate to children.
Anticoagulants ; Child ; Factor VIIa ; Fibrin ; Fibrinogen ; Glycosaminoglycans ; Hemostasis ; Humans ; Infant, Newborn ; Polymethacrylic Acids ; Proteins ; Thromboplastin

A pediatric patient with combined primary thrombocytopenic purpura and acquired hemolytic anemia (Evans syndrome), whose condition did not respond to treatment with prednisolone, has enjoyed long-term remission following a period of treatment with 6-Mercaptopurine.
6-Mercaptopurine/therapeutic use* ; Anemia, Hemolytic, Autoimmune/drug therapy* ; Child ; Human ; Male ; Purpura, Thrombocytopenic/drug therapy* ; Syndrome

No available abstract.
Leukemia, Myeloid, Acute*

No abstract available.
Heart Septal Defects, Ventricular*

No abstract available.
Intermittent Positive-Pressure Ventilation* ; Tetanus*

PURPOSE: Glutathione S-transferases (GSTs) are polymorphic genes. Absence of enzyme activity due to homozygous or heterozygous deletion of the gene is associated with reduced detoxification of carcinogens and potentially increasing the risk of cancer. METHODS: DNA was extracted from bone marrow aspirates of 26 acute lymphoblastic leukemia (ALL) patients and from peripheral blood of 13 controls. PCR amplification was used to assess GSTM1, GSTT1, and GSTP1 at codon 105 and 114 genotypes for cases and controls. RESULTS: We investigated the polymorphisms within the GSTM1, GSTT1, and GSTP1 genes in children with ALL. The null (absence of both alleles) genotype for GSTM1 was 2.6-fold [odd ratio (OR), 0.38; 95% confidence interval (CI), 0.1-1.5; P=0.043] increased in children with ALL, whereas the frequency of GSTT1 null genotype in ALL cases was not statistically different from that of controls. GSTP1 Val105/Val105 genotype showed a 1.6-fold (OR, 0.63; 95% CI, 0.16-2.43; P=0.38) increase in ALL in comparison to the combined category of Ile105/Val105 and Ile105/Ile105 genotypes. CONCLUSION: Our results suggest that polymorphisms within genes of the GST superfamily (especiallly GSTM1 null type) may be increased in childhood ALL.
Bone Marrow ; Carcinogens ; Child ; Codon ; DNA ; Genotype ; Glutathione Transferase* ; Glutathione* ; Humans ; Polymerase Chain Reaction ; Precursor Cell Lymphoblastic Leukemia-Lymphoma*